激活的IL-6信号参与CALR突变MPN发病并为难治靶点
本研究探讨CALR突变骨髓增殖性肿瘤(MPN)中IL-6信号通路的作用。CRISPR/Cas9构建的CALR 1型样缺失突变细胞获得细胞因子非依赖性并向巨核系分化,IL-6、gp130、IL-6R及p-JAK1/p-STAT3升高。靶向gp130、IL-6R或IL-6可抑制突变细胞增殖及患者CD34+细胞集落形成,TCZ与芦可替尼低纳摩尔浓度协同。
要点
- CALR突变细胞中IL-6/gp130/STAT3通路异常激活,呈细胞自主性。
- 野生型而非突变型CALR与gp130、IL-6R结合并下调其膜表达。
- 靶向IL-6信号可抑制CALR及JAK2V617F突变患者CD34+细胞集落形成。
核心结论
- 激活的IL-6信号参与CALR突变MPN的发病,靶向抑制IL-6信号可能具有治疗潜力。
- 研究支持突变CALR的功能缺失模型,导致gp130与IL-6R膜表达上调。
研究设计与样本
- 基础与体外研究,采用CRISPR/Cas9在UT7及UT7/mpl细胞中构建CALR 1型样(DEL)突变。
- 检测CALR突变患者及JAK2V617F突变患者来源的CD34+细胞。
主要发现
- CALR DEL细胞在无MPL刺激下IL-6 mRNA、细胞外释放IL-6、膜gp130、IL-6R、p-JAK1、p-STAT3及STAT3占据IL-6启动子均增加。
- CALR突变患者CD34+细胞IL-6 mRNA与p-STAT3水平升高。
- SC144、托珠单抗(TCZ)及IL-6抗体抑制CALR突变患者CD34+细胞的CFU-Mk生长。
- 靶向IL-6信号也减少JAK2V617F突变患者CD34+细胞的集落形成。
关键数值与推荐
- TCZ与芦可替尼在极低纳摩尔浓度下呈协同作用。
- SC-144靶向gp130,TCZ靶向IL-6R,两者及IL-6抗体均降低CALR DEL与CALR敲除细胞增殖。
临床怎么用
- 对CALR突变MPN可考虑评估IL-6/STAT3通路激活状态。
- TCZ联合芦可替尼的协同作用提示潜在联合治疗方向,尚需临床验证。
局限性
- 证据主要来自体外细胞系与患者CD34+细胞,缺乏体内模型与临床数据。
- 协同作用的具体浓度与临床剂量关系未在摘要中报告。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Calreticulin (CALR), an endoplasmic reticulum-associated chaperone, is frequently mutated in myeloproliferative neoplasms (MPNs). Mutated CALR promotes downstream JAK2/STAT5 signaling through interaction with, and activation of, the thrombopoietin receptor (MPL). Here, we provide evidence of a novel mechanism contributing to CALR-mutated MPNs, represented by abnormal activation of the interleukin 6 (IL-6)-signaling pathway. We found that UT7 and UT7/mpl cells, engineered by clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) to express the CALR type 1-like (DEL) mutation, acquired cytokine independence and were primed to the megakaryocyte (Mk) lineage. Levels of IL-6 messenger RNA (mRNA), extracellular-released IL-6, membrane-associated glycoprotein 130 (gp130), and IL-6 receptor (IL-6R), phosphorylated JAK1 and STAT3 (p-JAK1 and p-STAT3), and IL-6 promoter region occupancy by STAT3 all resulted in increased CALR DEL cells in the absence of MPL stimulation. Wild-type, but not mutated, CALR physically interacted with gp130 and IL-6R, downregulating their expression on the cell membrane. Agents targeting gp130 (SC-144), IL-6R (tocilizumab [TCZ]), and cell-released IL-6 reduced proliferation of CALR DEL as well as CALR knockout cells, supporting a mutated CALR loss-of-function model. CD34+ cells from CALR-mutated patients showed increased levels of IL-6 mRNA and p-STAT3, and colony-forming unit-Mk growth was inhibited by either SC144 or TCZ, as well as an IL-6 antibody, supporting cell-autonomous activation of the IL-6 pathway. Targeting IL-6 signaling also reduced colony formation by CD34+ cells of JAK2V617F-mutated patients. The combination of TCZ and ruxolitinib was synergistic at very low nanomolar concentrations. Overall, our results suggest that target inhibition of IL-6 signaling may have therapeutic potential in CALR, and possibly JAK2V617F, mutated MPNs.
引用
- Balliu M, Calabresi L, Bartalucci N, et al. Activated IL-6 signaling contributes to the pathogenesis of, and is a novel therapeutic target for, CALR-mutated MPNs. Blood Adv. 2021. PMID: 33890979. doi:10.1182/bloodadvances.2020003291
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。